HI SCR208

Requests the Department of Health to establish a Medicinal Psilocybin and Psilocin Working Group to examine the medicinal and therapeutic effects of these substances for treating mental health conditions.

Working group to examine federal, state, and local laws regarding medicinal use of psilocybin and psilocin; available medical and scientific research on safety and efficacy; and requirements for medical professionals to prescribe these substances.

If feasible, working group to develop a long-term strategic plan ensuring safe, accessible, and affordable medicinal psilocybin and psilocin products for adults 21 years or older.

Working group composition includes the Director of Health as chair, Attorney General, University of Hawaii faculty, legislative committee chairs, clinical practitioners, and representatives from Drug Policy Forum of Hawaii, Clarity Project, Hawaii Psychiatric Medical Association, and the psychedelics industry.

Preliminary report due 20 days before the 2022 legislative session and final report due 20 days before the 2023 legislative session; working group to be dissolved July 1, 2023.